361 related articles for article (PubMed ID: 33280442)
21. Therapeutic modulation of inflammasome pathways.
Chauhan D; Vande Walle L; Lamkanfi M
Immunol Rev; 2020 Sep; 297(1):123-138. PubMed ID: 32770571
[TBL] [Abstract][Full Text] [Related]
22. NLRP3 inflammasome: Its regulation and involvement in atherosclerosis.
Hoseini Z; Sepahvand F; Rashidi B; Sahebkar A; Masoudifar A; Mirzaei H
J Cell Physiol; 2018 Mar; 233(3):2116-2132. PubMed ID: 28345767
[TBL] [Abstract][Full Text] [Related]
23. Extracellular NLRP3 inflammasome particles are internalized by human coronary artery smooth muscle cells and induce pro-atherogenic effects.
Gaul S; Schaeffer KM; Opitz L; Maeder C; Kogel A; Uhlmann L; Kalwa H; Wagner U; Haas J; Behzadi A; Pelegrin P; Boeckel JN; Laufs U
Sci Rep; 2021 Jul; 11(1):15156. PubMed ID: 34312415
[TBL] [Abstract][Full Text] [Related]
24. Acute exposure of minimally oxLDL elicits survival responses by downregulating the mediators of NLRP3 inflammasome in cultured RAW 264.7 macrophages.
Thankam FG; Khwaja B; Nguyen M; Ahsan O; Agrawal DK
J Biochem; 2022 Oct; 172(5):265-276. PubMed ID: 35993502
[TBL] [Abstract][Full Text] [Related]
25. Melatonin Ameliorates the Progression of Atherosclerosis via Mitophagy Activation and NLRP3 Inflammasome Inhibition.
Ma S; Chen J; Feng J; Zhang R; Fan M; Han D; Li X; Li C; Ren J; Wang Y; Cao F
Oxid Med Cell Longev; 2018; 2018():9286458. PubMed ID: 30254716
[TBL] [Abstract][Full Text] [Related]
26. Inflammasomes: a preclinical assessment of targeting in atherosclerosis.
Stitham J; Rodriguez-Velez A; Zhang X; Jeong SJ; Razani B
Expert Opin Ther Targets; 2020 Sep; 24(9):825-844. PubMed ID: 32757967
[TBL] [Abstract][Full Text] [Related]
27. NLRP3 Inflammasome in Acute Myocardial Infarction.
Mauro AG; Bonaventura A; Mezzaroma E; Quader M; Toldo S
J Cardiovasc Pharmacol; 2019 Sep; 74(3):175-187. PubMed ID: 31356555
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial DAMPs and altered mitochondrial dynamics in OxLDL burden in atherosclerosis.
Khwaja B; Thankam FG; Agrawal DK
Mol Cell Biochem; 2021 Apr; 476(4):1915-1928. PubMed ID: 33492610
[TBL] [Abstract][Full Text] [Related]
29. Xanthine Oxidase Induces Foam Cell Formation through LOX-1 and NLRP3 Activation.
Dai Y; Cao Y; Zhang Z; Vallurupalli S; Mehta JL
Cardiovasc Drugs Ther; 2017 Feb; 31(1):19-27. PubMed ID: 28084571
[TBL] [Abstract][Full Text] [Related]
30. Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome.
Rajamäki K; Nordström T; Nurmi K; Åkerman KE; Kovanen PT; Öörni K; Eklund KK
J Biol Chem; 2013 May; 288(19):13410-9. PubMed ID: 23530046
[TBL] [Abstract][Full Text] [Related]
31. DAMPs as mediators of sterile inflammation in aging-related pathologies.
Feldman N; Rotter-Maskowitz A; Okun E
Ageing Res Rev; 2015 Nov; 24(Pt A):29-39. PubMed ID: 25641058
[TBL] [Abstract][Full Text] [Related]
32. Cell-Specific Roles of NLRP3 Inflammasome in Myocardial Infarction.
Takahashi M
J Cardiovasc Pharmacol; 2019 Sep; 74(3):188-193. PubMed ID: 31356542
[TBL] [Abstract][Full Text] [Related]
33. Glucose regulates hypoxia-induced NLRP3 inflammasome activation in macrophages.
Watanabe S; Usui-Kawanishi F; Karasawa T; Kimura H; Kamata R; Komada T; Inoue Y; Mise N; Kasahara T; Takahashi M
J Cell Physiol; 2020 Oct; 235(10):7554-7566. PubMed ID: 32115713
[TBL] [Abstract][Full Text] [Related]
34. Novel Role for Tranilast in Regulating NLRP3 Ubiquitination, Vascular Inflammation, and Atherosclerosis.
Chen S; Wang Y; Pan Y; Liu Y; Zheng S; Ding K; Mu K; Yuan Y; Li Z; Song H; Jin Y; Fu J
J Am Heart Assoc; 2020 Jun; 9(12):e015513. PubMed ID: 32476536
[TBL] [Abstract][Full Text] [Related]
35. Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-κB innate response pathways.
Rahman MM; McFadden G
J Virol; 2011 Dec; 85(23):12505-17. PubMed ID: 21957307
[TBL] [Abstract][Full Text] [Related]
36. Targeting NLRP3 inflammasome as a promising approach for treatment of diabetic nephropathy: Preclinical evidences with therapeutic approaches.
Ram C; Jha AK; Ghosh A; Gairola S; Syed AM; Murty US; Naidu VGM; Sahu BD
Eur J Pharmacol; 2020 Oct; 885():173503. PubMed ID: 32858047
[TBL] [Abstract][Full Text] [Related]
37. NLRP3 inflammasome in endothelial dysfunction.
Bai B; Yang Y; Wang Q; Li M; Tian C; Liu Y; Aung LHH; Li PF; Yu T; Chu XM
Cell Death Dis; 2020 Sep; 11(9):776. PubMed ID: 32948742
[TBL] [Abstract][Full Text] [Related]
38. Aldehyde dehydrogenase 2 inhibited oxidized LDL-induced NLRP3 inflammasome priming and activation via attenuating oxidative stress.
Xu Y; Yuan Q; Cao S; Cui S; Xue L; Song X; Li Z; Xu R; Yuan Q; Li R
Biochem Biophys Res Commun; 2020 Sep; 529(4):998-1004. PubMed ID: 32819611
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-155 promotes the ox-LDL-induced activation of NLRP3 inflammasomes via the ERK1/2 pathway in THP-1 macrophages and aggravates atherosclerosis in ApoE-/- mice.
Yin R; Zhu X; Wang J; Yang S; Ma A; Xiao Q; Song J; Pan X
Ann Palliat Med; 2019 Nov; 8(5):676-689. PubMed ID: 31865729
[TBL] [Abstract][Full Text] [Related]
40. NLRP3 inflammasome as a treatment target in atherosclerosis: A focus on statin therapy.
Parsamanesh N; Moossavi M; Bahrami A; Fereidouni M; Barreto G; Sahebkar A
Int Immunopharmacol; 2019 Aug; 73():146-155. PubMed ID: 31100709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
